Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists

Cardiovascular Diabetology

Volumn 12, Issue 1, 2013, Pages

  Fruchart, Jean Charles ^a  

^a Fondation coeur et arteres   (France)

Author keywords

Cardiovascular; Diabetes; Fibrate; K 877; Metabolic syndrome; Peroxisome proliferator activated receptor; SPPARM

Indexed keywords

ALEGLITAZAR; FENOFIBRATE; GFT 505; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; K 877; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANTILIPEMIC AGENT; FIBRIC ACID DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ABDOMINAL OBESITY; CARDIOVASCULAR RISK; DRUG MECHANISM; DYSLIPIDEMIA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; AGONISTS; CARDIOVASCULAR DISEASE; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; RISK FACTOR;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FIBRIC ACIDS; HUMANS; HYPOLIPIDEMIC AGENTS; PPAR ALPHA; PPAR GAMMA; RISK FACTORS;

EID: 84878349086     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-12-82     Document Type: Review

References (57)

1. World Health Organisation cardiovascular disease statistics. Fact sheet No. 317. http://www.who.int/mediacentre/factsheets/fs317/en/index.html.
2. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R, Cholesterol Treatment Trialists' (CTT) Collaboration Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376:1670-1681. 10.1016/S0140-6736(10)61350-5, 2988224, 21067804, Cholesterol Treatment Trialists' (CTT) Collaboration.
3. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R, Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278. Cholesterol Treatment Trialists' (CTT) Collaborators.
4. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C, Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008, 371:117-125. 10.1016/S0140-6736(08)60104-X, 18191683, Cholesterol Treatment Trialists' (CTT) Collaborators.
5. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003, 348:383-393. 10.1056/NEJMoa021778, 12556541.
6. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, Collins R, Thompson SG, Danesh J, Emerging Risk Factors Collaboration Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009, 302:1993-2000. 3284229, 19903920, Emerging Risk Factors Collaboration.
7. Millán Núñez-Cortthomamper J, Montoya JP, Salas XP, Hernández Mijares A, Carey VJ, Hermans MP, Sacks FM, Fruchart JC. The REALIST (REsiduAl risk, LIpids and Standard Therapies) study: an analysis of residual risk attributable to lipid profile in acute coronary syndrome. Endocrinol Nutr 2011, 58:38-47. 10.1016/j.endonu.2010.10.004, 21208833.
8. Carey VJ, Bishop L, Laranjo N, Harshfield BJ, Kwiat C, Sacks FM. Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control. Am J Cardiol 2010, 106:757-763. 10.1016/j.amjcard.2010.05.002, 20816113.
9. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syvänne M, op Reimer WJ S, Vrints C, Wood D, Zamorano JL, Zannad F, European Association for Cardiovascular Prevention & Rehabilitation (EACPR); ESC Committee for Practice Guidelines (CPG) European guidelines on cardiovascular disease prevention in clinical practice 2012: The Fifth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice. Eur Heart J 2012, 33:1635-1701. European Association for Cardiovascular Prevention & Rehabilitation (EACPR); ESC Committee for Practice Guidelines (CPG).
10. Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Borén J, Catapano AL, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Nordestgaard BG, Ray KK, Reiner Z, Taskinen MR, Tokgözoglu L, Tybjærg-Hansen A, Watts GF, European Atherosclerosis Society Consensus Panel Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011, 32:1345-1361. 10.1093/eurheartj/ehr112, 3105250, 21531743, European Atherosclerosis Society Consensus Panel.
11. International Diabetes Federation Global guidelines for Type 2 diabetes 2012. http://www.idf.org/global-guideline-type-2-diabetes-2012.
12. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M, FIELD study investigators Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366:1849-1861. FIELD study investigators.
13. Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC, Cushman WC, Simons-Morton DG, Byington RP, ACCORD Study Group Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010, 362:1563-1574. 2879499, 20228404, ACCORD Study Group.
14. Fruchart JC. Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease. Atherosclerosis 2009, 205:1-8. 10.1016/j.atherosclerosis.2009.03.008, 19386311.
15. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987, 317:1237-1245. 10.1056/NEJM198711123172001, 3313041.
16. The BIP Study Group Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000, 102:21-27. The BIP Study Group.
17. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999, 341:410-418. 10.1056/NEJM199908053410604, 10438259.
18. Sacks FM, Carey VJ, Fruchart JC. Combination lipid therapy in type 2 diabetes. N Engl J Med 2010, 363:692-694.
19. Rajamani K, Colman PG, Li LP, Best JD, Voysey M, D'Emden MC, Laakso M, Baker JR, Keech AC, FIELD study investigators Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): A prespecified analysis of a randomised controlled trial. Lancet 2009, 373:1780-1788. 10.1016/S0140-6736(09)60698-X, 2687887, 19465233, FIELD study investigators.
20. Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TM, Moffitt MS, Taskinen MR, Simes RJ, Tse D, Williamson E, Merrifield A, Laatikainen LT, d'Emden MC, Crimet DC, O'Connell RL, Colman PG, FIELD study investigators Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007, 370:1687-1697. 10.1016/S0140-6736(07)61607-9, 17988728, FIELD study investigators.
21. Davis TM, Ting R, Best JD, Donoghoe MW, Drury PL, Sullivan DR, Jenkins AJ, O'Connell RL, Whiting MJ, Glasziou PP, Simes RJ, Kesäniemi YA, Gebski VJ, Scott RS, Keech AC, Fenofibrate Intervention and Event Lowering in Diabetes Study investigators Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia 2011, 54:280-290. 10.1007/s00125-010-1951-1, 21052978, Fenofibrate Intervention and Event Lowering in Diabetes Study investigators.
22. Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, Hubbard L, Esser BA, Lovato JF, Perdue LH, Goff DC, Cushman WC, Ginsberg HN, Elam MB, Genuth S, Gerstein HC, Schubart U, Fine LJ, ACCORD Study Group; ACCORD Eye Study Group Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010, 363:233-244. ACCORD Study Group; ACCORD Eye Study Group.
23. Scott R, O'Brien R, Fulcher G, Pardy C, D'Emden M, Tse D, Taskinen MR, Ehnholm C, Keech A, Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009, 32:493-498. 10.2337/dc08-1543, 2646035, 18984774, Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators.
24. Hottelart C, el Esper N, Achard JM, Pruna A, Fournier A. Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency. Nephrologie 1999, 20:41-44.
25. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990, 347:645-650. 10.1038/347645a0, 2129546.
26. Dietz M, Mohr P, Kuhn B, Maerki HP, Hartman P, Ruf A, Benz J, Grether U, Wright MB. Comparative molecular profiling of the PPARalpha/gamma activator aleglitazar: PPAR selectivity, activity and interaction with cofactors. Chem Med Chem 2012, 7:1101-1111. 3504387, 22489042.
27. Fruchart JC, Duriez P, Staels B. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol 1999, 10:245-257. 10.1097/00041433-199906000-00007, 10431661.
28. Fruchart JC, Staels B, Duriez P. PPARS, metabolic disease and atherosclerosis. Pharmacol Res 2001, 44:345-352. 10.1006/phrs.2001.0871, 11712864.
29. Fruchart JC, Duriez P, Staels B. Molecular mechanism of action of the fibrates. J Soc Biol 1999, 193:67-75.
30. Fruchart JC, Duriez P. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Drugs Today (Barc) 2006, 42:39-64.
31. Neve BP, Corseaux D, Chinetti G, Zawadzki C, Fruchart JC, Duriez P, Staels B, Jude B. PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation 2001, 103:207-212. 10.1161/01.CIR.103.2.207, 11208678.
32. Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, Fruchart JC, Tedgui A, Haegeman G, Staels B. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem 1999, 274:32048-32054. 10.1074/jbc.274.45.32048, 10542237.
33. Roberts LD, Murray AJ, Menassa D, Ashmore T, Nicholls AW, Griffin JL. The contrasting roles of PPARdelta and PPARgamma in regulating the metabolic switch between oxidation and storage of fats in white adipose tissue. Genome Biol 2011, 12:R75. 10.1186/gb-2011-12-8-r75, 3245615, 21843327.
34. Gervois P, Fruchart JC, Staels B. Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors. Nat Clin Pract Endocrinol Metab 2007, 3:145-156. 10.1038/ncpendmet0397, 17237841.
35. Fruchart JC, Davignon J, Bard JM, Grothe AM, Richard A, Fievet C. Effect of fenofibrate treatment on type III hyperlipoproteinemia. Am J Med 1987, 83:71-74. 10.1016/0002-9343(87)90874-6, 3688011.
36. Duez H, Lefebvre B, Poulain P, Torra IP, Percevault F, Luc G, Peters JM, Gonzalez FJ, Gineste R, Helleboid S, Dzavik V, Fruchart JC, Fiévet C, Lefebvre P, Staels B. Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation. Arterioscler Thromb Vasc Biol 2005, 25:585-591. 10.1161/01.ATV.0000154140.73570.00, 15618549.
37. Tenenbaum A, Fisman EZ. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?. Cardiovasc Diabetol 2012, 11:140. 10.1186/1475-2840-11-140, 3502168, 23150952.
38. Lewis JS, Jordan VC. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance. Mutat Res 2005, 591:247-263. 10.1016/j.mrfmmm.2005.02.028, 16083919.
39. Balint BL, Nagy L. Selective modulators of PPAR activity as new therapeutic tools in metabolic diseases. Endocr Metab Immune Disord Drug Targets 2006, 6:33-43. 10.2174/187153006776056620, 16611163.
40. Higgins SL, dePaoli AM. Selective peroxisome proliferator-activated receptor gamma (PPARγ) modulation as a strategy for safer therapeutic PPARγ activation. Am J Clin Nutr 2010, 91:267S-272S. 10.3945/ajcn.2009.28449E, 19906796.
41. Doshi LS, Brahma MK, Bahirat UA, Dixit AV, Nemmani KV. Discovery and development of selective PPAR gamma modulators as safe and effective antidiabetic agents. Expert Opin Investig Drugs 2010, 19:489-512. 10.1517/13543781003640169, 20367191.
42. Rosenson RS, Wright RS, Farkouh M, Plutzky J. Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects. Am Heart J 2012, 164:672-680. 10.1016/j.ahj.2012.06.023, 23137497.
43. Younk LM, Uhl L, Davis SN. Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk. Expert Opin Drug Metab Toxicol 2011, 7:753-763. 10.1517/17425255.2011.579561, 21521130.
44. Henry RR, Lincoff AM, Mudaliar S, Rabbia M, Chognot C, Herz M. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet 2009, 374:126-135. 10.1016/S0140-6736(09)60870-9, 19515415.
45. Herz M, Gaspari F, Perico N, Viberti G, Urbanowska T, Rabbia M, Wieczorek Kirk D. Effects of high dose aleglitazar on renal function in patients with type 2 diabetes. Int J Cardiol 2011, 151:136-142. 10.1016/j.ijcard.2010.08.037, 20837369.
46. Investor update 2012: Roche's aleglitazar renal safety study AleNephro meets primary endpoint. http://www.roche.com/investors/ir_update/inv-update-2012-11-05.htm.
47. Fruchart JC. Novel peroxisome proliferator activated receptor-alpha agonists. Am J Cardiol 2007, 100(Suppl 11A):n41-n46.
48. Cariou B, Zair Y, Staels B, Bruckert E. Effects of the new dual PPAR alpha/delta agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism. Diabetes Care 2011, 34:2008-2014. 10.2337/dc11-0093, 3161281, 21816979.
49. Tailleux A, Wouters K, Staels B. Roles of PPARs in NAFLD: potential therapeutic targets. Biochim Biophys Acta 1821, 2012:809-818.
50. Ishibashi S, Arai H, Yamashita S, Araki E, Yamada N, Ishibashi S, Arai H, Yamashita S, Araki E, Yamada N. Benefical effects of K-877, a potent and highly selective PPARα agonist, on plasma lipoprotein profile in patients with atherogenic dyslipidemia. Abstract 525. http://www.kenes.com/eas2012/abstracts/pdf/525.pdf.
51. Ishibashi S, Yamashita S, Arai H, Araki E, Yamada N. Suppression of postprandial triglyceride, Remnant-like Particles-Cholesterol (RLP-C) and ApoB48 surge by K-877, a potent and highly selective PPARα agonist. Abstract 618. http://www.kenes.com/eas2012/abstracts/pdf/618.pdf.
52. Takizawa T. K-877, a highly potent and selective PPARα agonist, improves dyslipidemia and atherosclerosis in experimental animal models. Abstract 787. http://www.kenes.com/eas2012/abstracts/pdf/787.pdf.
53. Yamazaki Y, Abe K, Toma T, Nishikawa M, Ozawa H, Okuda A, Araki T, Oda S, Inoue K, Shibuya K, Staels B, Fruchart JC. Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor alpha agonists. Bioorg Med Chem Lett 2007, 17:4689-4693. 10.1016/j.bmcl.2007.05.066, 17553678.
54. Harano Y, Miyawaki T, Nabiki J, Shibachi M, Adachi T, Ikeda M, Ueda F, Nakano T. Development of cookie test for the simultaneous determination of glucose intolerance, hyperinsulinemia, insulin resistance and postprandial dyslipidemia. Endocr J 2006, 53:173-180. 10.1507/endocrj.53.173, 16618974.
55. Varbo A, Benn M, Tybjærg-Hansen A, Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol 2013, 61:427-436. 10.1016/j.jacc.2012.08.1026, 23265341.
56. Canto C, Auwerx J. Cell biology: FGF21 takes a fat bite. Science 2012, 336:675-676. 10.1126/science.1222646, 3616235, 22582248.
57. Ong KL, Rye KA, O'Connell R, Jenkins AJ, Brown C, Xu A, Sullivan DR, Barter PJ, Keech AC, FIELD study investigators Long-term fenofibrate therapy increases Fibroblast Growth Factor 21 and Retinol-Binding Protein 4 in subjects with type 2 diabetes. J Clin Endocrinol Metab 2012, 97:4701-4708. 10.1210/jc.2012-2267, 23144467, FIELD study investigators.